Visweswaran Navaratnam
Research Subjects
Research Interests
Visweswaran Navaratnam has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Didier Menard
Malaria Genetics and Resistance Team (MEGATEAM), UR 3073 - Pathogens Host Arthropods Vectors Interactions Unit, Université de Strasbourg, Strasbourg, France
1 shared publication - Duong Socheat
National Center for Parasitology, Entomology and Malaria Control, Phnom Penh, Cambodia
1 shared publication - Frédéric Ariey
Department of Parasites and Insect Vectors, Institut Pasteur, Paris, France.
1 shared publication - Jean-René Kiechel
Drugs for Neglected Diseases Initiative, Geneva, Switzerland
1 shared publication - Pharath Lim
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA; National Center for Parasitology, Entomology, and Malaria Control, Phnom Penh, Cambodia
1 shared publication - Rithea Leang
National Center for Parasitology, Entomology & Malaria Control, Phnom Penh, Cambodia
1 shared publication
Latest Publications
- Open Access
- 23 September 2013
- Published by Springer Nature in Malaria Journal
- Vol. 12 (1) , 343
Therapeutic efficacy of fixed dose artesunate-mefloquine for the treatment of acute, uncomplicated Plasmodium falciparum malaria in Kampong Speu, Cambodia
Cambodia stopped using co-blistered, non-fixed, artesunate-mefloquine (ASMQ) in 2008 when treatment failure rates approximated 20%. Fixed dose combination (FDC) ASMQ is efficacious against acute uncomplicated, drug resistant Plasmodium falciparum malaria in Southeast Asia but has not been tested in Cambodia.
- 23 September 2013
- Published by Springer Nature in Malaria Journal
- Vol. 12 (1) , 343
Open AccessTherapeutic efficacy of fixed dose artesunate-mefloquine for the treatment of acute, uncomplicated Plasmodium falciparum malaria in Kampong Speu, Cambodia
Cambodia stopped using co-blistered, non-fixed, artesunate-mefloquine (ASMQ) in 2008 when treatment failure rates approximated 20%. Fixed dose combination (FDC) ASMQ is efficacious against acute uncomplicated, drug resistant Plasmodium falciparum malaria in Southeast Asia but has not been tested in Cambodia.